Clinical trialPhase 1 / Phase 2Completed
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 17 December 2012
- Expected end
- 13 August 2020
- Enrollment
- 515 participants
- Sites
- 12
- Primary outcomes
- Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events; Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death; Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events; Objective Response Rate (ORR) by Independent Central Review (ICR); Objective Response Rate by Local Assessment
- Sponsor
- Industry
- Results posted
- 2021-04-06
- Last update
- 12 August 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 14
- Registry-listed results paperSacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final res… DOI 10.1016/j.annonc.2020.09.004↗
- Registry-listed results paperSacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. DOI 10.1056/nejmoa1814213↗
- Registry-listed results paperTherapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop… DOI 10.1158/1078-0432.ccr-17-0933↗
- Registry-listed results paperSacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial … DOI 10.1002/cncr.30789↗
- Registry-listed results paperTherapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. DOI 10.1200/jco.2016.72.1894↗
- Registry-listed results paperEfficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patie… DOI 10.1200/jco.2016.70.8297↗
- Registry-listed results paperEnhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Goviteca… DOI 10.1158/1078-0432.ccr-15-0670↗
- Registry-listed results paperFirst-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diver… DOI 10.1158/1078-0432.ccr-14-3321↗
- Builds on itSacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From … DOI 10.1111/cts.70291↗
- Builds on itSacituzumab Govitecan-hziy in Breast Cancer. DOI 10.1097/coc.0000000000000919↗
- Builds on itSacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and… DOI 10.1016/j.annonc.2021.03.005↗
- Builds on itSacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carc… DOI 10.1016/j.clgc.2015.10.002↗
- Builds on itSacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancre… DOI 10.1021/acs.bioconjchem.5b00223↗
- BackgroundSacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply. DOI 10.1056/nejmc1903943↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.